The phase 1 clinical trial that assessed the activity and safety of avelumab (MSB0010718C) demonstrated PD-L1 blockade produced antitumor responses in NSCLC (Gulley et al., 2017), UC (Apolo et al., 2017), breast cancer (Dirix et al., 2018), adrenocortical carcinoma (Le Tourneau et al., 2018), melanoma (Keilholz et al., 2019), mesothelioma (Hassan et al., 2019), ovarian cancer (Disis et al., 2019), RCC (Vaishampayan et al., 2019). The gene discussed is CD274; the disease is non-small cell lung carcinoma.